Apellis Pharmaceuticals Inc Prix / Ventes
Quel est le Prix / Ventes de Apellis Pharmaceuticals Inc?
Le Prix / Ventes de Apellis Pharmaceuticals Inc est 8.64
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Health Care secteur sur NASDAQ par rapport à Apellis Pharmaceuticals Inc
Que fait Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Entreprises avec prix / ventes similaire à Apellis Pharmaceuticals Inc
- Relaxo Footwears a Prix / Ventes de 8.62
- I Synergy a Prix / Ventes de 8.63
- Codebase Ventures a Prix / Ventes de 8.63
- Aquila European Renewables Income Fund a Prix / Ventes de 8.63
- PI Industries a Prix / Ventes de 8.64
- Astrotech Corp a Prix / Ventes de 8.64
- Apellis Pharmaceuticals Inc a Prix / Ventes de 8.64
- MFS Municipal Income Trust a Prix / Ventes de 8.64
- Neurocrine Biosciences a Prix / Ventes de 8.64
- Koolearn Technology a Prix / Ventes de 8.64
- Urban&Civic plc a Prix / Ventes de 8.65
- Central Wealth a Prix / Ventes de 8.65
- Labrador Iron Ore Royalty a Prix / Ventes de 8.65